All In Biotech

Drug Trial Radar · NCT01474798

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Feb 29, 2012

Primary completion

Oct 31, 2012

Study completion Dec 31, 2012

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.

Conditions

  • Acne Vulgaris

Interventions

  • RA-18C3Drug

    For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection. For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: 100 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Moy, Fincher, and Chipps Facial Plastics and Dermatology

    Beverly Hills, California

  • Meridien Research

    St. Petersburg, Florida

  • Austin Dermatology Associates

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.